As of January 17, 2023, 96.3 percent of adults in Ireland had been fully vaccinated against COVID-19. According to the manufacturers of the majority of COVID-19 vaccines currently in use in Europe, being fully vaccinated is when a person receives two doses of the vaccine. In Portugal, 94.2 percent of adults had received a full course of the COVID-19 vaccination, as well as 93.9 percent of those in Malta had been fully vaccinated. On the other hand, only 35.8 percent of adults in Bulgaria had been fully vaccinated.

Furthermore, the seven-day rate of cases across Europe shows which countries are currently worst affected by the situation. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

On 6/16/2023 CDPH replaced the booster measures with a new “Up to Date” measure based on CDC’s new recommendations, replacing the primary series, boosted, and bivalent booster metrics The definition of “primary series complete” has not changed and is based on previous recommendations that CDC has since simplified. A person cannot complete their primary series with a single dose of an updated vaccine. Whereas the booster measures were calculated using the eligible population as the denominator, the new up to date measure uses the total estimated population. Please note that the rates for some groups may change since the up to date measure is calculated differently than the previous booster and bivalent measures.

This data is from the same source as the Vaccine Progress Dashboard at https://covid19.ca.gov/vaccination-progress-data/ which summarizes vaccination data at the county level by county of residence. Where county of residence was not reported in a vaccination record, the county of provider that vaccinated the resident is included. This applies to less than 1% of vaccination records. The sum of county-level vaccinations does not equal statewide total vaccinations due to out-of-state residents vaccinated in California.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

Totals for the Vaccine Progress Dashboard and this dataset may not match, as the Dashboard totals doses by Report Date and this dataset totals doses by Administration Date. Dose numbers may also change for a particular Administration Date as data is updated.

Previous updates:

• On March 3, 2023, with the release of HPI 3.0 in 2022, the previous equity scores have been updated to reflect more recent community survey information. This change represents an improvement to the way CDPH monitors health equity by using the latest and most accurate community data available. The HPI uses a collection of data sources and indicators to calculate a measure of community conditions ranging from the most to the least healthy based on economic, housing, and environmental measures.

• Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 16+ and age 5+ denominators have been uploaded as archived tables.

• Starting on May 29, 2021 the methodology for calculating on-hand inventory in the shipped/delivered/on-hand dataset has changed. Please see the accompanying data dictionary for details. In addition, this dataset is now down to the ZIP code level.

NOTE: This dataset replaces a previous one. Please see below. Chicago residents who are up to date with COVID-19 vaccines by ZIP Code, based on the reported home address and age group of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). “Up to date” refers to individuals who meet the CDC’s updated COVID-19 vaccination criteria based on their age and prior vaccination history. For surveillance purposes, up to date is defined based on the following criteria: People ages 5 years and older: · Are up to date when they receive 1+ doses of a COVID-19 vaccine during the current season. Children ages 6 months to 4 years: · Children who have received at least two prior COVID-19 vaccine doses are up to date when they receive one additional dose of COVID-19 vaccine during the current season, regardless of vaccine product. · Children who have received only one prior COVID-19 vaccine dose are up to date when they receive one additional dose of the current season's Moderna COVID-19 vaccine or two additional doses of the current season's Pfizer-BioNTech COVID-19 vaccine. · Children who have never received a COVID-19 vaccination are up to date when they receive either two doses of the current season's Moderna vaccine or three doses of the current season's Pfizer-BioNTech vaccine. This dataset takes the place of a previous dataset, which covers doses administered from December 15, 2020 through September 13, 2023 and is marked as historical: - https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccinations-by-ZIP-Code/553k-3xzc. Data Notes: Weekly cumulative totals of people up to date are shown for each combination ZIP Code and age group. Note there are rows where age group is "All ages" so care should be taken when summing rows. Coverage percentages are calculated based on the cumulative number of people in each ZIP Code and age group who are considered up to date as of the week ending date divided by the estimated number of people in that subgroup. Population counts are obtained from the 2020 U.S. Decennial Census. For ZIP Codes mostly outside Chicago, coverage percentages are not calculated reliable Chicago-only population counts are not available. Actual counts may exceed population estimates and lead to coverage estimates that are greater than 100%, especially in smaller ZIP Codes with smaller populations. Additionally, the medical provider may report a work address or incorrect home address for the person receiving the vaccination, which may lead to over- or underestimation of vaccination coverage by geography. All coverage percentages are capped at 99%. Weekly cumulative counts and coverage percentages are reported from the week ending Saturday, September 16, 2023 onward through the Saturday prior to the dataset being updated. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. The Chicago Department of Public Health uses the most complete data available to estimate COVID-19 vaccination coverage among Chicagoans, but there are several limitations that impact our estimates. Individuals may receive vaccinations that are not recorded in the Illinois immunization registry, I-CARE, such as those administered in another state, causing underestimation of the number individuals who are up to date. Inconsistencies in records of separate doses administered to the same person, such as slight variations in dates of birth, can result in duplicate records for a person and underestimate the number of people who are up to date. For all datasets related to COVID-19, please

Overall US COVID-19 Vaccine administration and vaccine equity data at county level. Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

In the United States, influenza vaccination rates differ greatly by age. For example, during the 2022-2023 flu season, around 70 percent of those aged 65 years and older received an influenza vaccination, compared to just 35 percent of those aged 18 to 49 years. The CDC recommends that everyone six months and older in the United States should get vaccinated against influenza every year, with a few exceptions. Although influenza is mild for most people it can lead to hospitalization and even death, especially among the young, the old, and those with certain preexisting conditions.

The impact of flu vaccinations Flu vaccinations are safe and effective, preventing thousands of illnesses, medical visits, and deaths every year. However, the effectiveness of flu vaccines varies each year depending on what flu viruses are circulating that season and the age and health status of the person receiving the vaccination. During the 2022-2023 flu season it was estimated that influenza vaccination prevented almost 31 thousand hospitalizations among those aged 65 years and older. In addition, flu vaccinations prevented 2,479 deaths among those aged 65 years and older as well as 63 deaths among children six months to four years.

The burden of influenza The impact of influenza is different from season to season. However, during the 2022-2023 flu season there were around 31 million cases of influenza in the United States. Furthermore, there were around 21,000 deaths due to influenza, an increase from the previous year but significantly fewer than in 2017-2018 when influenza contributed to 51,000 deaths. Most of these deaths are among the elderly. In 2022-2023 the death rate due to influenza among those aged 65 years and older was around 26.6 per 100,000 population. In comparison, those aged 18 to 49 years had an influenza death rate of just .7 per 100,000 population.

Percentages of children and pregnant women who have received recommended vaccines, by target population and vaccine/antigen covering results from the 2011, 2013, 2015, 2017, 2019, and 2021 cycles of the Childhood National Immunization Coverage Survey.

This table will no longer be updated after 5/30/2024 given the end of the 2023-2024 viral respiratory vaccine season. This table shows the cumulative number and percentage of CT residents who have received an updated COVID-19 vaccine during the 2023-2024 viral respiratory season by age group (current age). CDC recommends that people get at least one dose of this vaccine to protect against serious illness, whether or not they have had a COVID-19 vaccination before. Children and people with moderate to severe immunosuppression might be recommended more than one dose. For more information on COVID-19 vaccination recommendations, click here. • Data are reported weekly on Thursday and include doses administered to Saturday of the previous week (Sunday – Saturday). All data in this report are preliminary. Data from the previous week may be changed because of delays in reporting, deduplication, or correction of errors. • These analyses are based on data reported to CT WiZ which is the immunization information system for CT. CT providers are required by law to report all doses of vaccine administered. CT WiZ also receives records on CT residents vaccinated in other jurisdictions and by federal entities which share data with CT Wiz electronically. Electronic data exchange is being added jurisdiction-by-jurisdiction. Currently, this includes Rhode Island and New York City but not Massachusetts and New York State. Therefore, doses administered to CT residents in neighboring towns in Massachusetts and New York State will not be included. A full list of the jurisdiction with which CT has established electronic data exchange can be seen at the bottom of this page (https://portal.ct.gov/immunization/Knowledge-Base/Articles/Vaccine-Providers/CT-WiZ-for-Vaccine-Providers-and-Training/Query-and-Response-functionality-in-CT-WiZ?language=en_US) • Population size estimates used to calculate cumulative percentages are based on 2020 DPH provisional census estimates*. • People are included if they have an active jurisdictional status in CT WiZ at the time weekly data are pulled. This excludes people who live out of state, are deceased and a small percentage who have opted out of CT WiZ. DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020, State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

NOTE: As of 2/16/2023, this table is not being updated. For data on COVID-19 updated (bivalent) booster coverage by town please to go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Town/bqd5-4jgh.

This table shows the number and percent of residents of each CT town that have initiated COVID-19 vaccination, are fully vaccinated and who have received additional dose 1.

All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected.

In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose.

A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations.

The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported.

Percentages are calculated using 2019 census data (https://portal.ct.gov/DPH/Health-Information-Systems--Reporting/Population/Annual-Town-and-County-Population-for-Connecticut).

Town of residence is verified by geocoding the reported address and then mapping it to a town using municipal boundaries. If an address cannot be geocoded, the reported town is used, if available. People for whom an address is not currently available are shown in this table as “Address pending validation”. Out-of-state residents vaccinated by CT providers are excluded from the table.

Town-level coverage estimates have been capped at 100%. Observed coverage may be greater than 100% for multiple reasons, including census denominator data not including all individuals that currently reside in the town (e.g., part time residents, change in population size since the census), errors in address data or other reporting errors. Also, the percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated when records for an individual cannot be linked because of differences in how names or date of birth are reported.

Caution should be used when interpreting coverage estimates for towns with large college/university populations since coverage may be underestimated. In the census, college/university students who live on or just off campus would be counted in the college/university town. However, if a student was vaccinated while studying remotely in his/her hometown, the student may be counted as a vaccine recipient in that town.

SVI refers to the CDC's Social Vulnerability Index - a measure that combines 15 demographic variables to identify communities most vulnerable to negative health impacts from disasters and public health crises. Measures of social vulnerability include socioeconomic status, household composition, disability, race, ethnicity, language, and transportation limitations - among others. Towns with a "yes" in the "Has SVI tract >0.75" field are those that have at least one census tract that is in the top quartile of vulnerability (e.g., a high-need area). 34 towns in Connecticut have at least one census tract in the top quartile for vulnerability.

Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction. Doses administered by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) are not yet reported to CT WiZ.  Data reported here reflect the vaccination records currently reported to CT WiZ.

Note: This dataset takes the place of the original "COVID-19 Vaccinations by Town" dataset (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Town/pdqi-ds7f) , which will not be updated after 4/15/2021. A breakdown of vaccinations by town and by age group is also available here: https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Town-and-Age-Group/gngw-ukpw .

As part of continuous data quality improvement efforts, duplicate records were removed from the COVID-19 vaccination data during the weeks of 4/19/2021 and 4/26/2021.

This statistical report, co-authored with the UK Health Security Agency (UKSHA), reports childhood vaccination coverage statistics for England in 2021-22. Data relates to the routine vaccinations offered to all children up to the age of 5 years, derived from the Cover of Vaccination Evaluated Rapidly (COVER). Additional information on children aged 2 and 3 vaccinated against seasonal flu are collected from GPs through UKHSA's ImmForm system.

• Weekly COVID-19 vaccination coverage estimates among children 6 months to 17 years is assessed through the National Immunization Survey (https://www.cdc.gov/vaccines/imz-managers/nis/about.html).

• Weekly estimates of COVID-19 vaccination coverage among children through December 31, 2023, were calculated using data from the National Immunization Survey-Child COVID Module (NIS-CCM) (https://www.cdc.gov/vaccines/imz-managers/nis/about.html#nis-ccm). Beginning January 2, 2024, the NIS-CCM was discontinued, and questions regarding receipt of COVID-19 vaccination among children were added to the NIS-Flu (https://www.cdc.gov/vaccines/imz-managers/nis/about.html#nis-cim).

• Starting in September 2023, the CDC recommended the 2023-2024 updated COVID-19 vaccine to protect against serious illness from COVID-19.

This dataset contains immunization status of kindergarten students in California in schools. Explanation of the different immunizations is in the attached data dictionary. The California Health and Safety Code Section 120325-75 requires students to provide proof of immunization for school and child care entry. Additionally, California Health and Safety Code Section 120375 and California Code of Regulation Section 6075 require all schools and child care facilities to assess and report annually the immunization status of their enrollees.

The annual kindergarten assessment is conducted each fall to monitor compliance with the California School Immunization law. Results from this assessment are used to measure immunization coverage among students entering kindergarten. Not all schools reported. This data set presents results from the kindergarten assessment and immunization coverage in kindergarten schools by county. To review individual school coverage and exemption rates in a separate lookup format, go to the School Lookup page at the Immunization Branch's Shots for School website: http://www.shotsforschool.org/lookup/

To see the PDF reports by year go to:https://www.shotsforschool.org/k-12/reporting-data/

See the attached file 'Notes on Methods' for data suppression in the '2016-17 ' data and after.

For earlier years of data: https://www.shotsforschool.org/k-12/reporting-data/

BackgroundImmunizations are one of the most effective tools a community can use to increase overall health and decrease the burden of vaccine-preventable diseases. Nevertheless, socioeconomic status, geographical location, education, and a child's sex have been identified as contributing to inequities in vaccine uptake in low- and middle-income countries (LMICs). Madagascar follows the World Health Organization's Extended Programme on Immunization (EPI) schedule, yet vaccine distribution remains highly inequitable throughout the country. This systematic review sought to understand the differences in EPI vaccine uptake between boys and girls in Madagascar.MethodsA systematic literature search was conducted in August 2021 through MEDLINE, the Cochrane Library, Global Index Medicus, and Google Scholar to identify articles reporting sex-disaggregated vaccination rates in Malagasy children. Gray literature was also searched for relevant data. All peer-reviewed articles reporting sex-disaggregated data on childhood immunizations in Madagascar were eligible for inclusion. Risk of bias was assessed using a tool designed for use in systematic reviews. Data extraction was conducted with a pre-defined data extraction tool. Sex-disaggregated data were synthesized to understand the impact of a child's sex on vaccination status.FindingsThe systematic search identified 585 articles of which a total of three studies were included in the final data synthesis. One additional publication was included from the gray literature search. Data from included articles were heterogeneous and, overall, indicated similar vaccination rates in boys and girls. Three of the four articles reported slightly higher vaccination rates in girls than in boys. A meta-analysis was not conducted due to the heterogeneity of included data. Six additional barriers to immunization were identified: socioeconomic status, mother's education, geographic location, supply chain issues, father's education, number of children in the household, and media access.InterpretationThe systematic review revealed the scarcity of available sex-stratified immunization data for Malagasy children. The evidence available was limited and heterogeneous, preventing researchers from conclusively confirming or denying differences in vaccine uptake based on sex. The low vaccination rates and additional barriers identified here indicate a need for increased focus on addressing the specific obstacles to vaccination in Madagascar. A more comprehensive assessment of sex-disaggregated vaccination status of Malagasy children and its relationship with such additional obstacles is recommended. Further investigation of potential differences in vaccination status will allow for the effective implementation of strategies to expand vaccine coverage in Madagascar equitably.Funding and registrationAH, BT, FM, GN, and RR are supported by a grant from the Bill and Melinda Gates Foundation (grant number: OPP1205877). The review protocol is registered in the Prospective Register of Systematic Reviews (PROSPERO ID: CRD42021265000).

As of 2023, nearly 81 percent of female adolescents aged 17 years in the U.S. had received one or more doses of an HPV vaccine. This statistic shows the percentage of female adolescents in the U.S. who had received a human papillomavirus (HPV) vaccine as of 2023, by age.

Flu vaccine uptake (%) in adults aged 65 and over, who received the flu vaccination between 1st September to the end of February as recorded in the GP record. The February collection has been adopted for our end of season figures from 2017 to 2018. All previous data is the same definitions but until the end of January rather than February to consider data returning from outside the practice and later in practice vaccinations.RationaleInfluenza (also known as Flu) is a highly infectious viral illness spread by droplet infection. The flu vaccination is offered to people who are at greater risk of developing serious complications if they catch the flu. The seasonal influenza programme for England is set out in the Annual Flu Letter. Both the flu letter and the flu plan have the support of the Chief Medical Officer (CMO), Chief Pharmaceutical Officer (CPhO), and Director of Nursing.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine-preventable communicable diseases. Immunisation is one of the most effective healthcare interventions available, and flu vaccines can prevent illness and hospital admissions among these groups of people. Increasing the uptake of the flu vaccine among these high-risk groups should also contribute to easing winter pressure on primary care services and hospital admissions. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The UK Health Security Agency (UKHSA) will continue to provide expert advice and monitoring of public health, including immunisation. NHS England now has responsibility for commissioning the flu programme, and GPs continue to play a key role. NHS England teams will ensure that robust plans are in place locally and that high vaccination uptake levels are reached in the clinical risk groups. For more information, see the Green Book chapter 19 on Influenza.The Annual Flu Letter sets out the national vaccine uptake ambitions each year. In 2021 to 2022, the national ambition was to achieve at least 85 percent vaccine uptake in those aged 65 and over. Prior to this, the national vaccine uptake ambition was 75 percent, in line with WHO targets.Definition of numeratorNumerator is the number of vaccinations administered during the influenza season between 1st September and the end of February.Definition of denominatorDenominator is the GP registered population on the date of extraction including patients who have been offered the vaccine but refused it, as the uptake rate is measured against the overall eligible population. For more detailed information please see the user guide, available to view and download from https://www.gov.uk/government/collections/vaccine-uptake#seasonal-flu-vaccine-uptakeCaveatsRead codes are primarily used for data collection purposes to extract vaccine uptake data for patients who fall into one or more of the designated clinical risk groups. The codes identify individuals at risk, and therefore eligible for flu vaccination. However, it is important to note that there may be some individuals with conditions not specified in the recommended risk groups for vaccination, who may be offered influenza vaccine by their GP based on clinical judgement and according to advice contained in the flu letter and Green Book, and thus are likely to fall outside the listed Read codes. Therefore, this data should not be used for GP payment purposes.

The annual pre-kindergarten (pre-K) through 12th grade school immunization survey collects school-level, grade-specific data on vaccine coverage and exemptions. The survey collects vaccination and exemption status data on children who entered the school system on or before a specified date during the fall semester. Individual vaccine information on each student is not collected. This table shows the percentage of kindergarten students vaccinated for each school-entry mandated vaccine series and the percentage with vaccination exemptions (medical or religious) reported by school. Percentage of students vaccinated is the number of students with the required number of doses of a given vaccine divided by the total number of students. Data includes all schools who reported students in kindergarten. School-mandated vaccine series for students enrolled in kindergarten are inactivated polio, DTaP (diphtheria, tetanus, and acellular pertussis), MMR (measles, mumps, and rubella), hepatitis B, varicella, and hepatitis A. Each child has 1 of 4 possible vaccination statuses: Vaccinated, Exempt (Religious), Exempt (Medical) or Not Complete. The criteria shown below are used to assess whether a child is considered vaccinated. • Polio = at least 3 doses of inactivated polio vaccine, with the last dose on or after their 4th birthday. This is a school entry requirement starting in kindergarten. • DTaP = at least 4 doses of DTaP vaccine, with the last dose on or after their 4th birthday. This is a school entry requirement starting in kindergarten. • MMR = at least 2 doses of MMR vaccine separated by at least 28 days, with the 1st dose on or after their 1st birthday. This is a school entry requirement starting in kindergarten. • HepB = at least 3 doses of hepatitis B vaccine, with the last dose on or after 24 weeks of age. This is a school entry requirement starting in kindergarten. • Varicella = at least 2 doses of varicella vaccine separated by at least 28 days, with the 1st dose on or after their 1st birthday, or a reliable history of chickenpox disease. This is a school entry requirement starting in kindergarten. • HepA = at least 2 doses of hepatitis A vaccine, given a minimum of six calendar months apart, with the 1st dose on or after their 1st birthday. This is a school entry requirement starting in kindergarten. • All = Percentage of students with all above vaccine series required for that grade level. Children without a record of vaccination, but with serologic proof of immunity to certain diseases (measles, mumps, rubella, hepatitis B, hepatitis A, and varicella), meet school entry requirements and may be counted as vaccinated. The values for schools with fewer than 30 enrolled kindergarteners are suppressed, and those fields are left blank.   Data Limitations and Considerations: • The school level data shown here are as tabulated and reported by schools and discrepancies may exist. • The Immunization Program identifies outliers and internally inconsistent data points and works with schools to resolve any data quality issues, when possible. • CT DPH cannot verify the accuracy of vaccine data for individual children or whether the documentation necessary to claim an exemption has been submitted. • Data are collected at the beginning of the school year, by which time vaccines are due. As the year progresses, immunization rates may increase as additional children receive required immunizations. Additionally, the student body is dynamic and as students arrive and leave school, the immunization rates are impacted. • Vaccine status is assessed on the level of the child and not on each vaccine. Once a child is listed as exempt, vaccination data is no longer collected in the survey for that child. Therefore, children with exemptions are not counted as vaccinated in the vaccine level assessments although they may have received some vaccines. • One school was excluded due to a data collection error.

NOTE: As of 2/16/2023, this table is no longer being updated. For data on COVID-19 Updated (Bivalent) Booster Coverage by Age go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Age-/j2me-7k56. For information on COVID-19 vaccination primary series coverage for people less than 5 years go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccination-Primary-Series-Coverage-Age-L/su9q-qn6e

Important change as of June 1, 2022

As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages for state- and county-level tables (except coverage by CT SVI priority zip code). 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator.

This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated, and addition dose 1 by age group. Age is based on age at the time of administration of the first dose.

All data in this report are preliminary; data for previous dates will be updated as new reports are received, and data errors are corrected.

Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used.

In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose.

A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations.

The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported.

Town-level coverage estimates have been capped at 100%. Observed coverage may be greater than 100% for multiple reasons, including census denominator data not including all individuals that currently reside in the town (e.g., part time residents, change in population size since the census), errors in address data or other reporting errors. Also, the percent with at least one dose many be over-estimated, and the percent fully

Splitgraph serves as an HTTP API that lets you run SQL queries directly on this data to power Web applications. For example:

See the Splitgraph documentation for more information.

According to the estimates of the World Health Organization and the UNICEF, China has achieved over 96 percent coverage rates for 12 different vaccines in 2022. The coverage of the Bacillus Calmette–Guérin (BCG) vaccine, primarily used against tuberculosis, has remained at 99 percent.

Present state of the market Until recently, foreign pharmaceutical companies were required to conduct clinical trials in China before they could manufacture the a vaccine for the Chinese market. However, in 2017, the Chinese Food and Drug Administration (CFDA) relaxed the aforementioned requirement to improve the ease of doing business with foreign vaccine manufacturing companies. The response of the vaccine producing market to this regulation change was positive, resulting in an almost immediate expansion of the sector. Even though foreign participants were now able to access the market with more ease, domestic manufacturing of vaccines still accounted for a vast majority of the vaccines produced in China.

Moving on from the one-child policy In 2018, China had a birth rate of approximately four times that of the USA, which has been further boosted by the relaxation of the one-child policy in China. Along with China’s commitment to universal vaccination of infants, it is likely that the market for immunizations only keep growing.

Monthly Cumulative Number and Percent of Persons Who Received ≥1 Influenza Vaccination Doses, by Flu Season, Age Group, and Jurisdiction

• Influenza vaccination coverage for children and adults is assessed through U.S. jurisdictions’ Immunization Information Systems (IIS) data, submitted from jurisdictions to CDC monthly in aggregate by age group. More information about the IIS can be found at https://www.cdc.gov/vaccines/programs/iis/about.html.

• Influenza vaccination coverage estimate numerators include the number of people receiving at least one dose of influenza vaccine in a given flu season, based on information that state, territorial, and local public health agencies report to CDC. Some jurisdictions’ data may include data submitted by tribes. Estimates include persons who are deceased but received a vaccination during the current season. People receiving doses are attributed to the jurisdiction in which the person resides unless noted otherwise. Quality and completeness of data may vary across jurisdictions. Influenza vaccination coverage denominators are obtained from 2020 U.S. Census Bureau population estimates.

• Monthly estimates shown are cumulative, reflecting all persons vaccinated from July through a given month of that flu season. Cumulative estimates include any historical data reported since the previous submission. National estimates are not presented since not all U.S. jurisdictions are currently reporting their IIS data to CDC. Jurisdictions reporting data to CDC include U.S. states, some localities, and territories.

• Because IIS data contain all vaccinations administered within a jurisdiction rather than a sample, standard errors were not calculated and statistical testing for differences in estimates across years were not performed.

• Laws and policies regarding the submission of vaccination data to an IIS vary by state, which may impact the completeness of vaccination coverage reflected for a jurisdiction. More information on laws and policies are found at https://www.cdc.gov/vaccines/programs/iis/policy-legislation.html.

• Coverage estimates based on IIS data are expected to differ from National Immunization Survey (NIS) estimates for children (https://www.cdc.gov/flu/fluvaxview/dashboard/vaccination-coverage-race.html) and adults (https://www.cdc.gov/flu/fluvaxview/dashboard/vaccination-adult-coverage.html) because NIS estimates are based on a sample that may not be representative after survey weighting and vaccination status is determined by survey respondent rather than vaccine records or administrations, and quality and completeness of IIS data may vary across jurisdictions. In general, NIS estimates tend to overestimate coverage due to overreporting and IIS estimates may underestimate coverage due to incompleteness of data in certain jurisdictions.